BP-C2

Phase 1Small molecule

MMeabco A/S

BP-C2 is one of 37 small molecule programs targeting Prostate Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CarcinomaRecruiting

Prostate CarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

39 competitors in Prostate Carcinoma

#DrugCompanyPhaseTrials

Erleada

Johnson & Johnson

Approved

2 2

Nubeqa

Bayer

Approved

1 3

Ritalin

Farxiga

Jevtana

Balversa

Estrace

Lynparza

Lupron

Sun Pharmaceutical Industries, Inc.

Xtandi

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer

Completed·MMeabco A/S·Phase 2·NCT03627390·16 enrolled

Unspecified1 trial

Recommended Dose Estimation of BP-C2

Recruiting·MMeddoc·Phase 1·NCT04186585·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BP-C2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BP-C2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BP-C2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Meabco A/S company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMeabco A/S

BP-C2

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pancreatic Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News